Conference Coverage (NCVDG)

U.S. AIDS Vaccine Trials Focus on CTL Responses

Published in AIDS Weekly, May 26th, 1997

Measurement of cytotoxic lymphocyte responses is becoming a major focus of U.S. clinical trials of AIDS vaccines.

Individuals with long-term asymptomatic HIV infection have persistent HIV specific cytotoxic lymphocyte (CTL) responses (see AIDS Weekly, February 6, 1995), and a preponderance of evidence suggests that the cellular arm of the immune response is crucial for control of the virus.

CTL from at least one recipient of a candidate HIV vaccine can recognize nearly all known viral strains, according to Kent J. Wienhold of Duke University, Durham, North Carolina.

Wienhold discussed early findings from tests for HIV specific CTL...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry